1-cyclopentyl-3-methylaminopyrrolidine | 503067-84-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-cyclopentyl-3-methylaminopyrrolidine
• 英文别名: 1-Cyclopentyl-N-methylpyrrolidin-3-amine
• CAS: 503067-84-3
• 化学式: C₁₀H₂₀N₂
• 分子量: 168.282
• InChiKey: SHAULALTEOZQIV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Aza-Substituted Spiro Derivatives
  申请人：Jitsuoka Makoto

  公开号：US20090258871A1

  公开（公告）日：2009-10-15

  A compound of the following formula (I) or its pharmaceutically-acceptable salt is provided: [wherein X, Y, Z and W each independently represent a methine group or a nitrogen atom, provided that a case where all of X, Y, Z and W are methine group; A represents —O— or the like, B represents —C(O)— or the like, D represent —(CH 2 )m 2 -, —O— or the like, and m2 represents 0 or 1; Q represents a methine group or a nitrogen atom; and R represents a group represented by the following formula (II-1) (wherein R 6 , R 7 and R 8 independently represent a lower alkyl group or the like].

  提供以下式子（I）的化合物或其药学上可接受的盐：[其中X、Y、Z和W各自独立地表示甲基基团或氮原子，前提是当X、Y、Z和W全部为甲基基团时；A表示—O—或类似物，B表示—C（O）—或类似物，D表示—（CH2）m2-、—O—或类似物，m2表示0或1；Q表示甲基基团或氮原子；R表示由以下式子（II-1）表示的基团（其中R6、R7和R8各自独立地表示较低的烷基基团或类似物）。
• Carbamoyl-Substituted Spiro Derivative
  申请人：Jitsuoka Makoto

  公开号：US20080171753A1

  公开（公告）日：2008-07-17

  A compound represented by, e.g. the formula (I): [wherein X, Y, Z, and W each independently represent optionally substituted methine; A, B, and D each independently represent —C(O)—, etc.; Q represents a methine or a nitrogen; and R represents the formula (II-1), optionally substituted with lower alkyl, etc.; (wherein R 6 represents a lower alkyl, etc; and R 7 and R 8 each independently represents a lower alkyl, etc.)] or a pharmaceutically acceptable salt of the compound. The compounds and salt have antagonistic activity against a histamine H3 receptor or inverse agonistic activity against a histamine H3 receptor. They are useful in the prevention or treatment of metabolic diseases, circulatory diseases, or neurotic diseases.

  化合物的化学式为(I):[其中X、Y、Z和W各自独立地表示可选择性取代的甲烷基；A、B和D各自独立地表示—C(O)—等；Q表示甲烷基或氮；R表示化学式(II-1)，可选择性地取代较低的烷基等；(其中R6表示较低的烷基等；R7和R8各自独立地表示较低的烷基等)]或其药学上可接受的盐。这些化合物和盐对组胺H3受体具有拮抗活性或反向激动活性。它们可用于预防或治疗代谢性疾病、循环系统疾病或神经疾病。
• AZA-SUBSTITUTED SPIRO DERIVATIVES
  申请人：Jitsuoka Makoto

  公开号：US20120149703A1

  公开（公告）日：2012-06-14

  A compound of the following formula (I) or its pharmaceutically-acceptable salt is provided: [wherein X, Y, Z and W each independently represent a methine group or a nitrogen atom, provided that a case where all of X, Y, Z and W are methine group; A represents —O— or the like, B represents —C(O)— or the like, D represent —(CH 2 )m 2 -, —O— or the like, and m2 represents 0 or 1; Q represents a methine group or a nitrogen atom; and R represents a group represented by the following formula (II-1) (wherein R 6 , R 7 and R 8 independently represent a lower alkyl group or the like].

  提供以下式子（I）或其药学上可接受的盐的化合物： 其中X、Y、Z和W各自独立地表示一个甲基基团或氮原子，前提是X、Y、Z和W全部都是甲基基团的情况除外；A表示—O—或类似物，B表示—C（O）—或类似物，D表示—（CH2）m2-、—O—或类似物，m2表示0或1；Q表示一个甲基基团或氮原子；R表示以下式子（II-1）所表示的基团（其中R6、R7和R8各自独立地表示低级烷基或类似物）。
• THIA-TRIAZA-INDACENES
  申请人：Van Der Veen Lars

  公开号：US20120108618A1

  公开（公告）日：2012-05-03

  The present invention encompasses compounds of general formula (1) wherein R 1 to R 3 and X are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

  本发明涵盖了一般式（1）中R1至R3和X如权利要求1所定义的化合物，适用于治疗由过度或异常细胞增殖所特征的疾病，并用于制备具有上述性质的药物。
• [EN] FLUORINATED TRYPTAMINE COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME<br/>[FR] COMPOSÉS DE TRYPTAMINE FLUORÉS, ANALOGUES ASSOCIÉS ET MÉTHODES LES UTILISANT
  申请人：UNIV OF THE SCIENCES

  公开号：WO2022256554A1

  公开（公告）日：2022-12-08

  The present disclosure relates to fluorinated tryptamine compounds, or analogues thereof, and compositions comprising the same, that can be used to treat, prevent, and/or ameliorate a psychiatric disease or disorder in a subject.

  本公开涉及氟代色胺化合物，或其类似物，以及包含它们的组合物，可用于治疗、预防和/或改善受试者的精神疾病或障碍。